Navigation Links
S*BIO to Develop New JAK-2 Inhibitor for Treatment of Myeloproliferative Disorders and Hematological Malignancies
Date:9/10/2007

SINGAPORE, Sept. 11 /PRNewswire/ -- S*BIO Pte Ltd today announced the development of a novel and proprietary orally-administered compound, SB1518, for the treatment of myeloproliferative disorders (MPD) and certain hematological malignancies. MPD is believed to be caused by a specific mutation (V617F) of JAK2 and is a closely related group of hematological malignancies in which the bone marrow develops and functions abnormally. MPD is characterised by an excess of blood cells and the three main disorders include polycythemia vera (excess red blood cell mass), essential thrombocythemia (excess blood platelets) and myelofibrosis. S*BIO is a privately-held biotech company focusing on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer.

SB1518 is a small molecule JAK2-selective kinase inhibitor. It has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the activating V617F mutation which is found in high frequencies among three types of MPD and in some leukemias. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of MPD and other diseases.

"SB1518 has demonstrated excellent anti-proliferative and anti-tumor activity, combined with very good tolerability in relevant in vitro and in vivo models. SB1518 will address an important unmet medical need due to the lack of specific and effective long-term medical treatment for patients with MPD," said Dr. Jan-Anders Karlsson, CEO of S*BIO. "This promising new compound is our second success in the last twelve months and represents an important step in building S*BIO's strong pipeline of proprietary, targeted anti-cancer compounds."

In addition to SB1518, S*BIO has a robust pipeline including SB939, the company's lead histone deacetylase (HDAC) inhibitor which is currently in Phase 1 clinical trials. S*BIO's target-driven approach to innovative small molecule
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
3. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
4. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
5. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
6. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
7. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
8. CuraGen Presents Update on Clinical Development Program for Belinostat
9. Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos Bevirimat
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. Staphylococcus aureus vaccine development on track ? safe and immunogenic in Phase I clinicaltrials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014   Mast Therapeutics, Inc. ... today that Santosh Vetticaden, Chief Medical Officer and ... for personal reasons, in mid-September.  Edwin L. ... Aires Pharmaceuticals, which Mast acquired earlier this year, ... Company,s interim Chief Medical Officer.  Dr. Parsley previously ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... 2014 Does your doctor know what you,re smoking?  ... recommended marijuana to the over 112,000 currently registered patients under ... of the other roughly 20,300+ active physicians listed with the ... it – even though a poll in February 2014 showed ... have tried it. "With marijuana legalization underway, ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 10, 2011 MAQUET Cardiovascular, a leading provider ... signed a three-year, dual-source contract with Premier Healthcare ... the Premier membership.  The contract includes the CS300 ... 50cc IABP Catheter, SENSATION® 7Fr. IABP Catheter and ...
... PRINCETON, N.J., Oct. 10, 2011 Pharmasset, Inc. (Nasdaq: ... two treatment arms to the ELECTRON trial of PSI-7977, ... chronic hepatitis C (HCV). The rapid and consistent antiviral ... to date provided the rationale for additional exploratory regimens ...
Cached Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 2MAQUET Cardiovascular Awarded Three-Year Contract From Premier Healthcare Alliance for Intra-Aortic Balloon Pumps 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 2Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 3Pharmasset Announces Further Expansion of ELECTRON Trial in Hepatitis C 4
(Date:8/30/2014)... Saturday 30 August 2014: A new method ... external defibrillators (AEDs) was presented at ESC Congress today ... predictive method, Paris needs 350 AEDs located in public ... arrest (OHCA). , Dr Dahan said: "Out of hospital ... an annual incidence ranging between 50 and 100 per ...
(Date:8/30/2014)... Colorado (PRWEB) August 31, 2014 According to ... proven step by step holistic system for skin health. It ... has already been tried by more than 138,000 patients from ... by Mike Walden, who says that this method will not ... permanent clear skin. , What makes this program unique ...
(Date:8/30/2014)... 2014 Zensah®, the leader in compression technology ... emerge as a best-seller within golf and tennis. Golfers and ... they enjoy most by using the compression elbow sleeve to ... is a condition that causes pain on the inner side ... attach to the bony bump on the inside of your ...
(Date:8/30/2014)... The Truth about Six Pack Abs is a new method ... shocking foods that can burn belly fat, unique workouts that ... as some motivation secrets for successful fitness. , The author ... trick that can help users reduce junk-food cravings. , ... think, cardio exercise routines are not the best to be ...
(Date:8/30/2014)... 2014 Information supplied by insurance companies ... better prices to consumers in 2014. A group of ... when using the open system for adults at ... to use this year can help the average person ... location and not from medical histories. The finder tool ...
Breaking Medicine News(10 mins):Health News:New method predicts optimal number and location of AEDs 2Health News:Acne No More Review Reveals Unusual Tip to Eliminate Acne Permanently 2Health News:Relieve Golfers and Tennis Elbow Pain with the Zensah® Compression Elbow Sleeve 2Health News:Truth about Six Pack Abs Review Reveals Unique Method to Eliminate Stubborn Stomach Fat 2Health News:Term Life Insurance Rates Now Found Nationally by New Insurer Finder Tool 2
... 6 In a newly-published special supplement, the Journal ... prevent and treat venous thromboembolism (VTE), a major cause ... Lippincott Williams & Wilkins (LWW) is publishing ... that includes both the common medical condition of deep ...
... statement in observance of Pancreatic Cancer Awareness Month , WASHINGTON, ... yet it is the fourth leading cause of death by cancer ... be diagnosed with the disease and more than 35,000 will die ... find a cure for pancreatic cancer researchers have to know more ...
... role in boosting memories -- or forgetting them, researchers say ... remember the first time you smelled a type of flower? ... brain might. , In the study, published online Nov. ... objects to adult study participants. They paired the objects with ...
... small group of patients with severe Graves, eye disease ... vision following treatment with the drug rituximab. Inflammation ... were significantly reduced. The same patients had not previously ... disease. Raymond S. Douglas, M.D., Ph.D., an oculoplastics ...
... TORONTO, On November 6, 2009 Researchers at St. ... fire services across Ontario found that a bystander who attempts ... 50 per cent. But Dr. Laurie Morrison and the research ... per cent of bystanders in Toronto are willing to help, ...
... , COLUMBUS, Ohio, Nov. 6 The Ohio Association of ... health care premiums and less robust benefits if proposals being ... were to become law. , If the reforms proposed by ... in Ohio would increase 60% over five years in the ...
Cached Medicine News:Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 2Health News:Journal of Cardiovascular Nursing Urges Policies and Prevention To Reduce Deaths from Venous Thromboembolism 3Health News:New Smells 'Etched' in Brain: Study 2Health News:Researchers find new way to attack inflammation in Graves' eye disease 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 2Health News:Less than 1 in 3 Toronto bystanders who witness a cardiac arrest try to help: Study 3Health News:Congressional Health Care Reform Proposals Will Make Health Care More Expensive, Less Robust for Ohioans 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: